BN42082: A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis

June 18, 2021
https://clinicaltrials.gov/ct2/show/NCT04544436
Neurology, Multiple Sclerosis
Principal Investigator: Mirela Cerghet, MD
Multiple Sclerosis, Sclerosis, Autoimmune Diseases
Accepting Participants